drugset / Trial / NCT00852631

Seroquel XR in Adults With Schizophrenia

NCT00852631

Phase 3 Terminated 28 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally given, up to 600 mg once a day for 42 days.

Timeline

Start
2009-02
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 600 mg Oral

Indications